Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-Hydroxytryptamine-2 antagonist increases human slow wave sleep.

C Idzikowski, F J Mills, R Glennard

    Brain Research
    |July 16, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers.

    Journal of psychopharmacology (Oxford, England)·2012
    Same author

    British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.

    Journal of psychopharmacology (Oxford, England)·2010
    Same author

    Effects of meals on objective and subjective measures of daytime sleepiness.

    Journal of applied physiology (Bethesda, Md. : 1985)·1998
    Same author

    Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.

    PharmacoEconomics·1996
    Same author

    Impact of insomnia on health-related quality of life.

    PharmacoEconomics·1995
    Same author

    Insomnia and depression--sleep EEG changes.

    Journal of psychosomatic research·1994
    Same journal

    IGFBP3 and UBE2C are associated with protein modification pathways and serve as prognostic markers in glioma.

    Brain research·2026
    Same journal

    Targeting neurodevelopmental miR132-3p promotes neuroprotection and axon regeneration after optic nerve injury in mice.

    Brain research·2026
    Same journal

    Variability in acoustic startle response and prepulse inhibition across adulthood in Fragile X messenger ribonucleoprotein 1 knockout mice.

    Brain research·2026
    Same journal

    Transcriptome-guided modeling reveals insulin-related metabolic dysfunction in SCA3 mouse cerebellum.

    Brain research·2026
    Same journal

    Intranasal stromal cell-derived factor-1α mitigates parkinsonian deficits via dual modulation of neuroinflammation and gut microbiota in MPTP-induced models.

    Brain research·2026
    Same journal

    Emotions, the amygdala, and the right hemisphere.

    Brain research·2026
    See all related articles

    Ritanserin, a serotonin antagonist, doubled slow wave sleep duration in a placebo-controlled study. This finding challenges traditional theories on serotonin's role in sleep regulation.

    Area of Science:

    • Neuroscience
    • Sleep Medicine
    • Pharmacology

    Background:

    • Serotonin is traditionally thought to facilitate sleep.
    • The role of specific serotonin receptors in sleep architecture is not fully understood.

    Purpose of the Study:

    • To investigate the effects of a selective serotonin 5-HT2 antagonist on human sleep architecture.
    • To challenge existing theories of sleep control involving serotonin.

    Main Methods:

    • Double-blind, placebo-controlled sleep study involving human volunteers.
    • Administration of Ritanserin, a specific 5-HT2 antagonist.
    • Polysomnographic monitoring to assess sleep stages and duration.

    Main Results:

    • Ritanserin significantly increased the duration of slow wave sleep (stage 3).

    Related Experiment Videos

  • Stage 2 sleep duration decreased proportionally.
  • No insomnia or adverse effects on sleep initiation were observed.

    • Conclusions:

    • Selective 5-HT2 antagonism alters sleep architecture by increasing slow wave sleep.
    • This challenges the established view of serotonin as solely a sleep-facilitating agent.
    • Re-evaluation of serotonin's complex role in sleep control mechanisms is warranted.